Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 24;24(21):15539.
doi: 10.3390/ijms242115539.

Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies

André Balsa  1 , Rui Adão  1   2   3 , Carmen Brás-Silva  1   4
Affiliations
Review

Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies

André Balsa et al. Int J Mol Sci. .

Abstract

Pulmonary hypertension (PH) is a progressive condition that affects the pulmonary vessels, but its main prognostic factor is the right ventricle (RV) function. Many mice/rat models are used for research in PAH, but results fail to translate to clinical trials. This study reviews studies that test interventions on pulmonary artery banding (PAB), a model of isolated RV disfunction, and PH models. Multiple tested drugs both improved pulmonary vascular hemodynamics in PH models and improved RV structure and function in PAB animals. PH models and PAB animals frequently exhibited similar results (73.1% concordance). Macitentan, sildenafil, and tadalafil improved most tested pathophysiological parameters in PH models, but almost none in PAB animals. Results are frequently not consistent with other studies, possibly due to the methodology, which greatly varied. Some research groups start treating the animals immediately, and others wait up to 4 weeks from model induction. Treatment duration and choice of anaesthetic are other important differences. This review shows that many drugs currently under research for PAH have a cardioprotective effect on animals that may translate to humans. However, a uniformization of methods may increase comparability between studies and, thus, improve translation to clinical trials.

Keywords: preclinical studies; pulmonary arterial banding; pulmonary arterial hypertension; right ventricle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study selection.
See this image and copyright information in PMC

References

    1. Humbert M., Guignabert C., Bonnet S., Dorfmuller P., Klinger J.R., Nicolls M.R., Olschewski A.J., Pullamsetti S.S., Schermuly R.T., Stenmark K.R., et al. Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives. Eur. Respir. J. 2019;53:1801887. doi: 10.1183/13993003.01887-2018. - DOI - PMC - PubMed
    1. Howard L.S. Prognostic factors in pulmonary arterial hypertension: Assessing the course of the disease. Eur. Respir. Rev. 2011;20:236–242. doi: 10.1183/09059180.00006711. - DOI - PMC - PubMed
    1. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022;43:3618–3731. doi: 10.1093/eurheartj/ehac237. - DOI - PubMed
    1. Ruaro B., Salton F., Baratella E., Confalonieri P., Geri P., Pozzan R., Torregiani C., Bulla R., Confalonieri M., Matucci-Cerinic M., et al. An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics. 2022;12:616. doi: 10.3390/diagnostics12030616. - DOI - PMC - PubMed
    1. Sztuka K., Jasinska-Stroschein M. Animal models of pulmonary arterial hypertension: A systematic review and meta-analysis of data from 6126 animals. Pharmacol. Res. 2017;125:201–214. doi: 10.1016/j.phrs.2017.08.003. - DOI - PubMed